CD26/dipeptidylpeptidase IV—chemokine interactions: Double-edged regulation of inflammation and tumor biology

Journal of Leukocyte Biology

Volumn 99, Issue 6, 2016, Pages 955-969

  Mortier, Anneleen ^a   Gouwy, Mieke ^a   Van Damme, Jo ^a   Proost, Paul ^a   Struyf, Sofie ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Chemotaxis; Leukocyte; Post translational modification; Protease

Indexed keywords

AMINO ACID; CCL14 CHEMOKINE; CCL3L1 CHEMOKINE; CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BONE MARROW; CELL MIGRATION; CHEMOTAXIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KNOCKOUT MOUSE; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TUMOR IMMUNITY; ANIMAL; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CHEMOKINES; CHEMOTAXIS; DIPEPTIDYL PEPTIDASE 4; HIV; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84962694696     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3MR0915-401R     Document Type: Review

References (145)

1. Sallusto, F., Lanzavecchia, A. (2000) Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177, 134-140.
2. Struyf, S., Proost, P., Van Damme, J. (2003) Regulation of the immune response by the interaction of chemokines and proteases. Adv. Immunol. 81, 1-44.
3. Murphy, P. M. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol. Rev. 54, 227-229.
4. Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., Mantovani, A., Matsushima, K., Murphy, P. M., Nibbs, R., Nomiyama, H., Power, C. A., Proudfoot, A. E., Rosenkilde, M. M., Rot, A., Sozzani, S., Thelen, M., Yoshie, O., Zlotnik, A. (2014) International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66, 1-79.
5. Murphy, P. M., Baggiolini, M., Charo, I. F., Hèbert, C. A., Horuk, R., Matsushima, K., Miller, L. H., Oppenheim, J. J., Power, C. A. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176.
6. Mantovani, A., Bonecchi, R., Locati, M. (2006) Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6, 907-918.
7. Johnson, Z., Proudfoot, A. E., Handel, T. M. (2005) Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev. 16, 625-636.
8. Vanheule, V., Janssens, R., Boff, D., Kitic, N., Berghmans, N., Ronsse, I., Kungl, A. J., Amaral, F. A., Teixeira, M. M., Van Damme, J., Proost, P., Mortier, A. (2015) The positively charged COOH-terminal glycosaminoglycan binding CXCL9(74-103) peptide inhibits CXCL8-induced neutrophil extravasation and monosodium urate crystalinduced gout in mice. J. Biol. Chem. 290, 21292-21304.
9. Adage, T., Piccinini, A. M., Falsone, A., Trinker, M., Robinson, J., Gesslbauer, B., Kungl, A. J. (2012) Structure-based design of decoy chemokines as a way to explore the pharmacological potential of glycosaminoglycans. Br. J. Pharmacol. 167, 1195-1205.
10. Mortier, A., Van Damme, J., Proost, P. (2012) Overview of the mechanisms regulating chemokine activity and availability. Immunol. Lett. 145, 2-9.
11. Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S., Mantovani, A. (2000) The chemokine receptor switch paradigm and dendritic cell migration: its significance in tumor tissues. Immunol. Rev. 177, 141-149.
12. Gouwy, M., Schiraldi, M., Struyf, S., Van Damme, J., Uguccioni, M. (2012) Possible mechanisms involved in chemokine synergy fine tuning the inflammatory response. Immunol. Lett. 145, 10-14.
13. Gouwy, M., Struyf, S., Leutenez, L., Pörtner, N., Sozzani, S., Van Damme, J. (2014) Chemokines and other GPCR ligands synergize in receptor-mediated migration of monocyte-derived immature and mature dendritic cells. Immunobiology 219, 218-229.
14. Mortier, A., Van Damme, J., Proost, P. (2008) Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 120, 197-217.
15. Mortier, A., Gouwy, M., Van Damme, J., Proost, P. (2011) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654.
16. Van Damme, J., Struyf, S., Opdenakker, G. (2004) Chemokine-protease interactions in cancer. Semin. Cancer Biol. 14, 201-208.
17. Proost, P., Struyf, S., Couvreur, M., Lenaerts, J. P., Conings, R., Menten, P., Verhaert, P., Wuyts, A., Van Damme, J. (1998) Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J. Immunol. 160, 4034-4041.
18. Van Damme, J., Rampart, M., Conings, R., Decock, B., Van Osselaer, N., Willems, J., Billiau, A. (1990) The neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms. Eur. J. Immunol. 20, 2113-2118.
19. Mortier, A., Berghmans, N., Ronsse, I., Grauwen, K., Stegen, S., Van Damme, J., Proost, P. (2011) Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PLoS One 6, e23913.
20. Hèbert, C. A., Luscinskas, F. W., Kiely, J. M., Luis, E. A., Darbonne, W. C., Bennett, G. L., Liu, C. C., Obin, M. S., Gimbrone, Jr., M. A., Baker, J. B. (1990) Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J. Immunol. 145, 3033-3040.
21. Nourshargh, S., Perkins, J. A., Showell, H. J., Matsushima, K., Williams, T. J., Collins, P. D. (1992) A comparative study of the neutrophil stimulatory activity in vitro and pro-inflammatory properties in vivo of 72 amino acid and 77 amino acid IL-8. J. Immunol. 148, 106-111.
22. Walz, A., Baggiolini, M. (1990) Generation of the neutrophilactivating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J. Exp. Med. 171, 449-454.
23. Walz, A., Dewald, B., von Tscharner, V., Baggiolini, M. (1989) Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J. Exp. Med. 170, 1745-1750.
24. Proudfoot, A. E., Peitsch, M. C., Power, C. A., Allet, B., Mermod, J. J., Bacon, K., Wells, T. N. (1997) Structure and bioactivity of recombinant human CTAP-III and NAP-2. J. Protein Chem. 16, 37-49.
25. Iwata, S., Yamaguchi, N., Munakata, Y., Ikushima, H., Lee, J. F., Hosono, O., Schlossman, S. F., Morimoto, C. (1999) CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 11, 417-426.
26. Oravecz, T., Pall, M., Roderiquez, G., Gorrell, M. D., Ditto, M., Nguyen, N. Y., Boykins, R., Unsworth, E., Norcross, M. A. (1997) Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J. Exp. Med. 186, 1865-1872.
27. Proost, P., De Meester, I., Schols, D., Struyf, S., Lambeir, A. M., Wuyts, A., Opdenakker, G., De Clercq, E., Scharpè, S., Van Damme, J. (1998) Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273, 7222-7227.
28. Schols, D., Proost, P., Struyf, S., Wuyts, A., De Meester, I., Scharpè, S., Van Damme, J., De Clercq, E. (1998) CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity. Antiviral Res. 39, 175-187.
29. Struyf, S., De Meester, I., Scharpè, S., Lenaerts, J. P., Menten, P., Wang, J. M., Proost, P., Van Damme, J. (1998) Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28, 1262-1271.
30. Loos, T., Mortier, A., Gouwy, M., Ronsse, I., Put, W., Lenaerts, J. P., Van Damme, J., Proost, P. (2008) Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 112, 2648-2656.
31. Proost, P., Loos, T., Mortier, A., Schutyser, E., Gouwy, M., Noppen, S., Dillen, C., Ronsse, I., Conings, R., Struyf, S., Opdenakker, G., Maudgal, P. C., Van Damme, J. (2008) Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 205, 2085-2097.
32. Vossenaar, E. R., Zendman, A. J., van Venrooij, W. J., Pruijn, G. J. (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. BioEssays 25, 1106-1118.
33. Bezerra, G. A., Dobrovetsky, E., Dong, A., Seitova, A., Crombett, L., Shewchuk, L. M., Hassell, A. M., Sweitzer, S. M., Sweitzer, T. D., McDevitt, P. J., Johanson, K. O., Kennedy-Wilson, K. M., Cossar, D., Bochkarev, A., Gruber, K., Dhe-Paganon, S. (2012) Structures of human DPP7 reveal the molecular basis of specific inhibition and the architectural diversity of proline-specific peptidases. PLoS One 7, e43019.
34. Brandt, I., Lambeir, A. M., Maes, M. B., Scharpè, S., De Meester, I. (2006) Peptide substrates of dipeptidyl peptidases. Adv. Exp. Med. Biol. 575, 3-18.
35. Hopsu-Havu, V. K., Glenner, G. G. (1966) A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-b-naphthylamide. Histochemie 7, 197-201.
36. Lambeir, A. M., Durinx, C., Scharpè, S., De Meester, I. (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40, 209-294.
37. Mentlein, R. (1999) Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul. Pept. 85, 9-24.
38. De Meester, I., Korom, S., Van Damme, J., Scharpè, S. (1999) CD26, let it cut or cut it down. Immunol. Today 20, 367-375.
39. Broxmeyer, H. E., Hoggatt, J., O’Leary, H. A., Mantel, C., Chitteti, B. R., Cooper, S., Messina-Graham, S., Hangoc, G., Farag, S., Rohrabaugh, S. L., Ou, X., Speth, J., Pelus, L. M., Srour, E. F., Campbell, T. B. (2012) Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat. Med. 18, 1786-1796.
40. O’Leary, H., Ou, X., Broxmeyer, H. E. (2013) The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr. Opin. Hematol. 20, 314-319.
41. Ou, X., O’Leary, H. A., Broxmeyer, H. E. (2013) Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types. Blood 122, 161-169.
42. De Meester, I., Lambeir, A. M., Proost, P., Scharpè, S. (2003) Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV. Adv. Exp. Med. Biol. 524, 3-17.
43. Callebaut, C., Jacotot, E., Blanco, J., Krust, B., Hovanessian, A. G. (1998) Increased rate of HIV-1 entry and its cytopathic effect in CD4+/CXCR4+ T cells expressing relatively high levels of CD26. Exp. Cell Res. 241, 352-362.
44. Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A., Zaki, A., Fouchier, R. A., Thiel, V., Drosten, C., Rottier, P. J., Osterhaus, A. D., Bosch, B. J., Haagmans, B. L. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254.
45. Morimoto, C., Schlossman, S. F. (1998) The structure and function of CD26 in the T-cell immune response. Immunol. Rev. 161, 55-70.
46. Von Bonin, A., Hühn, J., Fleischer, B. (1998) Dipeptidyl-peptidase IV/CD26 on T cells: analysis of an alternative T-cell activation pathway. Immunol. Rev. 161, 43-53.
47. Christopherson, K. W., Cooper, S., Broxmeyer, H. E. (2003) Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood 101, 4680-4686.
48. Christopherson, K. W., Hangoc, G., Mantel, C. R., Broxmeyer, H. E. (2004) Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305, 1000-1003.
49. Yaron, A., Naider, F. (1993) Proline-dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28, 31-81.
50. Iwata, S., Morimoto, C. (1999) CD26/dipeptidyl peptidase IV in context. The different roles of a multifunctional ectoenzyme in malignant transformation. J. Exp. Med. 190, 301-306.
51. Pro, B., Dang, N. H. (2004) CD26/dipeptidyl peptidase IV and its role in cancer. Histol. Histopathol. 19, 1345-1351.
52. Havre, P. A., Abe, M., Urasaki, Y., Ohnuma, K., Morimoto, C., Dang, N. H. (2008) The role of CD26/dipeptidyl peptidase IV in cancer. Front. Biosci. 13, 1634-1645.
53. Bühling, F., Kunz, D., Reinhold, D., Ulmer, A. J., Ernst, M., Flad, H.-D., Ansorge, S. (1994) Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat. Immun. 13, 270-279.
54. Christopherson, K. W., Uralil, S. E., Porecha, N. K., Zabriskie, R. C., Kidd, S. M., Ramin, S. M. (2006) G-CSF- and GM-CSF-induced upregulation of CD26 peptidase downregulates the functional chemotactic response of CD34+CD382 human cord blood hematopoietic cells. Exp. Hematol. 34, 1060-1068.
55. Vanham, G., Kestens, L., De Meester, I., Vingerhoets, J., Penne, G., Vanhoof, G., Scharpè, S., Heyligen, H., Bosmans, E., Ceuppens, J. L., Gigase, P. (1993) Decreased expression of the memory marker CD26 on both CD4+ and CD8+ T lymphocytes of HIV-infected subjects. J. Acquir. Immune Defic. Syndr. 6, 749-757.
56. Fox, D. A., Hussey, R. E., Fitzgerald, K. A., Acuto, O., Poole, C., Palley, L., Daley, J. F., Schlossman, S. F., Reinherz, E. L. (1984) Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. J. Immunol. 133, 1250-1256.
57. Larrinaga, G., Perez, I., Sanz, B., Beitia, M., Errarte, P., Fernández, A., Blanco, L., Etxezarraga, M. C., Gil, J., López, J. I. (2015) Dipeptidylpeptidase IV activity is correlated with colorectal cancer prognosis. PLoS One 10, e0119436.
58. Yang, F., Zheng, T., Gao, Y., Baskota, A., Chen, T., Ran, X., Tian, H. (2014) Increased plasma DPP4 activity is an independent predictor of the onset of metabolic syndrome in Chinese over 4 years: result from the China National Diabetes and Metabolic Disorders Study. PLoS One 9, e92222.
59. Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D. M., Eckardt, K., Kaufman, J. M., Ryden, M., Müller, S., Hanisch, F. G., Ruige, J., Arner, P., Sell, H., Eckel, J. (2011) Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60, 1917-1925.
60. Röhrborn, D., Eckel, J., Sell, H. (2014) Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 588, 3870-3877.
61. Scheel-Toellner, D., Richter, E., Toellner, K.-M., Reiling, N., Wacker, H.-H., Flad, H.-D., Gerdes, J. (1995) CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma. Lab. Invest. 73, 685-690.
62. Gerli, R., Muscat, C., Bertotto, A., Bistoni, O., Agea, E., Tognellini, R., Fiorucci, G., Cesarotti, M., Bombardieri, S. (1996) CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin. Immunol. Immunopathol. 80, 31-37.
63. Kunkel, S. L., Lukacs, N., Kasama, T., Strieter, R. M. (1996) The role of chemokines in inflammatory joint disease. J. Leukoc. Biol. 59, 6-12.
64. Tourniaire, F., Romier-Crouzet, B., Lee, J. H., Marcotorchino, J., Gouranton, E., Salles, J., Malezet, C., Astier, J., Darmon, P., Blouin, E., Walrand, S., Ye, J., Landrier, J. F. (2013) Chemokine expression in inflamed adipose tissue is mainly mediated by NF-kB. PLoS One 8, e66515.
65. Proost, P., Struyf, S., Loos, T., Gouwy, M., Schutyser, E., Conings, R., Ronsse, I., Parmentier, M., Grillet, B., Opdenakker, G., Balzarini, J., Van Damme, J. (2006) Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res. Ther. 8, R107.
66. Kajiyama, H., Kikkawa, F., Maeda, O., Suzuki, T., Ino, K., Mizutani, S. (2002) Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology 63, 158-165.
67. Zhong, J., Maiseyeu, A., Davis, S. N., Rajagopalan, S. (2015) DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ. Res. 116, 1491-1504.
68. Deacon, C. F. (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13, 7-18.
69. Baggio, L. L., Drucker, D. J. (2006) Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu. Rev. Med. 57, 265-281.
70. Giampietro, O., Giampietro, C., Bartola, L. D., Masoni, M. C., Matteucci, E. (2013) Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des. Devel. Ther. 7, 99-104.
71. Dicker, D. (2011) DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34 (Suppl 2), S276-S278.
72. Femia, A. P., Raimondi, L., Maglieri, G., Lodovici, M., Mannucci, E., Caderni, G. (2013) Long-term treatment with sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int. J. Cancer 133, 2498-2503.
73. Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., Albert, M. L. (2015) Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol. 16, 850-858.
74. Hoffmann, T., Faust, J., Neubert, K., Ansorge, S. (1993) Dipeptidyl peptidase IV (CD 26) and aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett. 336, 61-64.
75. Ajami, K., Pitman, M. R., Wilson, C. H., Park, J., Menz, R. I., Starr, A. E., Cox, J. H., Abbott, C. A., Overall, C. M., Gorrell, M. D. (2008) Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett. 582, 819-825.
76. Proost, P., De Wolf-Peeters, C., Conings, R., Opdenakker, G., Billiau, A., Van Damme, J. (1993) Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J. Immunol. 150, 1000-1010.
77. Proost, P., Schutyser, E., Menten, P., Struyf, S., Wuyts, A., Opdenakker, G., Detheux, M., Parmentier, M., Durinx, C., Lambeir, A. M., Neyts, J., Liekens, S., Maudgal, P. C., Billiau, A., Van Damme, J. (2001) Aminoterminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 98, 3554-3561.
78. Ludwig, A., Schiemann, F., Mentlein, R., Lindner, B., Brandt, E. (2002) Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine. J. Leukoc. Biol. 72, 183-191.
79. Hensbergen, P. J., vander Raaij-Helmer, E. M., Dijkman, R., van der Schors, R. C., Werner-Felmayer, G., Boorsma, D. M., Scheper, R. J., Willemze, R., Tensen, C. P. (2001) Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. Eur. J. Biochem. 268, 4992-4999.
80. Proost, P., Mortier, A., Loos, T., Vandercappellen, J., Gouwy, M., Ronsse, I., Schutyser, E., Put, W., Parmentier, M., Struyf, S., Van Damme, J. (2007) Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110, 37-44.
81. Proost, P., Struyf, S., Schols, D., Durinx, C., Wuyts, A., Lenaerts, J. P., De Clercq, E., De Meester, I., Van Damme, J. (1998) Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha. FEBS Lett. 432, 73-76.
82. Shioda, T., Kato, H., Ohnishi, Y., Tashiro, K., Ikegawa, M., Nakayama, E. E., Hu, H., Kato, A., Sakai, Y., Liu, H., Honjo, T., Nomoto, A., Iwamoto, A., Morimoto, C., Nagai, Y. (1998) Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc. Natl. Acad. Sci. USA 95, 6331-6336.
83. Ohtsuki, T., Hosono, O., Kobayashi, H., Munakata, Y., Souta, A., Shioda, T., Morimoto, C. (1998) Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cellderived factor 1alpha by CD26/dipeptidyl peptidase IV. FEBS Lett. 431, 236-240.
84. Christopherson, K. W., Hangoc, G., Broxmeyer, H. E. (2002) Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J. Immunol. 169, 7000-7008.
85. Proost, P., Menten, P., Struyf, S., Schutyser, E., De Meester, I., Van Damme, J. (2000) Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 96, 1674-1680.
86. Struyf, S., Menten, P., Lenaerts, J. P., Put, W., D’Haese, A., De Clercq, E., Schols, D., Proost, P., Van Damme, J. (2001) Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur. J. Immunol. 31, 2170-2178.
87. Guan, E., Wang, J., Roderiquez, G., Norcross, M. A. (2002) Natural truncation of the chemokine MIP-1 beta /CCL4 affects receptor specificity but not anti-HIV-1 activity. J. Biol. Chem. 277, 32348-32352.
88. Guan, E., Wang, J., Norcross, M. A. (2004) Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV. J. Cell. Biochem. 92, 53-64.
89. Noso, N., Sticherling, M., Bartels, J., Mallet, A. I., Christophers, E., Schröder, J. M. (1996) Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts. J. Immunol. 156, 1946-1953.
90. Struyf, S., Proost, P., Schols, D., De Clercq, E., Opdenakker, G., Lenaerts, J. P., Detheux, M., Parmentier, M., De Meester, I., Scharpè, S., Van Damme, J. (1999) CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J. Immunol. 162, 4903-4909.
91. Mochizuki, M., Bartels, J., Mallet, A. I., Christophers, E., Schröder, J. M. (1998) IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J. Immunol. 160, 60-68.
92. Noso, N., Bartels, J., Mallet, A. I., Mochizuki, M., Christophers, E., Schröder, J. M. (1998) Delayed production of biologically active O-glycosylated forms of human eotaxin by tumor-necrosisfactor-alpha-stimulated dermal fibroblasts. Eur. J. Biochem. 253, 114-122.
93. Richter, R., Casarosa, P., Ständker, L., Münch, J., Springael, J. Y., Nijmeijer, S., Forssmann, W. G., Vischer, H. F., Vakili, J., Detheux, M., Parmentier, M., Leurs, R., Smit, M. J. (2009) Significance of N-terminal proteolysis of CCL14a to activity on the chemokine receptors CCR1 and CCR5 and the human cytomegalovirus-encoded chemokine receptor US28. J. Immunol. 183, 1229-1237.
94. Forssmann, U., Hartung, I., Bälder, R., Fuchs, B., Escher, S. E., Spodsberg, N., Dulkys, Y., Walden, M., Heitland, A., Braun, A., Forssmann, W. G., Elsner, J. (2004) n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. J. Immunol. 173, 3456-3466.
95. Proost, P., Struyf, S., Schols, D., Opdenakker, G., Sozzani, S., Allavena, P., Mantovani, A., Augustyns, K., Bal, G., Haemers, A., Lambeir, A. M., Scharpè, S., Van Damme, J., De Meester, I. (1999) Truncation of macrophage-derived chemokine by CD26/ dipeptidylpeptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J. Biol. Chem. 274, 3988-3993.
96. Struyf, S., Proost, P., Sozzani, S., Mantovani, A., Wuyts, A., De Clercq, E., Schols, D., Van Damme, J. (1998) Enhanced anti-HIV-1 activity and altered chemotactic potency of NH2-terminally processed macrophagederived chemokine (MDC) imply an additional MDC receptor. J. Immunol. 161, 2672-2675.
97. Pal, R., Garzino-Demo, A., Markham, P. D., Burns, J., Brown, M., Gallo, R. C., DeVico, A. L. (1997) Inhibition of HIV-1 infection by the betachemokine MDC. Science 278, 695-698.
98. Lambeir, A. M., Proost, P., Durinx, C., Bal, G., Senten, K., Augustyns, K., Scharpè, S., Van Damme, J., De Meester, I. (2001) Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 276, 29839-29845.
99. Van Coillie, E., Proost, P., Van Aelst, I., Struyf, S., Polfliet, M., De Meester, I., Harvey, D. J., Van Damme, J., Opdenakker, G. (1998) Functional comparison of two human monocyte chemotactic protein-2 isoforms, role of the amino-terminal pyroglutamic acid and processing by CD26/dipeptidyl peptidase IV. Biochemistry 37, 12672-12680.
100. Salanga, C. L., Handel, T. M. (2011) Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317, 590-601.
101. Sadir, R., Imberty, A., Baleux, F., Lortat-Jacob, H. (2004) Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J. Biol. Chem. 279, 43854-43860.
102. McQuibban, G. A., Butler, G. S., Gong, J. H., Bendall, L., Power, C., Clark-Lewis, I., Overall, C. M. (2001) Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508.
103. Vanhoof, G., Goossens, F., De Meester, I., Hendriks, D., Scharpè, S. (1995) Proline motifs in peptides and their biological processing. FASEB J. 9, 736-744.
104. Crump, M. P., Gong, J. H., Loetscher, P., Rajarathnam, K., Amara, A., Arenzana-Seisdedos, F., Virelizier, J. L., Baggiolini, M., Sykes, B. D., Clark-Lewis, I. (1997) Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16, 6996-7007.
105. Tilton, B., Ho, L., Oberlin, E., Loetscher, P., Baleux, F., Clark-Lewis, I., Thelen, M. (2000) Signal transduction by CXC chemokine receptor 4. Stromal cell-derived factor 1 stimulates prolonged protein kinase B and extracellular signal-regulated kinase 2 activation in T lymphocytes. J. Exp. Med. 192, 313-324.
106. Broxmeyer, H. E. (2008) Chemokines in hematopoiesis. Curr. Opin. Hematol. 15, 49-58.
107. Aiuti, A., Webb, I. J., Bleul, C., Springer, T., Gutierrez-Ramos, J. C. (1997) The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185, 111-120.
108. DeLa Luz Sierra, M., Yang, F., Narazaki, M., Salvucci, O., Davis, D., Yarchoan, R., Zhang, H. H., Fales, H., Tosato, G. (2004) Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity. Blood 103, 2452-2459.
109. Detheux, M., Ständker, L., Vakili, J., Münch, J., Forssmann, U., Adermann, K., Pöhlmann, S., Vassart, G., Kirchhoff, F., Parmentier, M., Forssmann, W. G. (2000) Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR)1 and CCR5 agonist with anti-HIV properties. J. Exp. Med. 192, 1501-1508.
110. Vakili, J., Ständker, L., Detheux, M., Vassart, G., Forssmann, W. G., Parmentier, M. (2001) Urokinase plasminogen activator and plasmin efficiently convert hemofiltrate CC chemokine 1 into its active. J. Immunol. 167, 3406-3413.
111. Sabroe, I., Hartnell, A., Jopling, L. A., Bel, S., Ponath, P. D., Pease, J. E., Collins, P. D., Williams, T. J. (1999) Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J. Immunol. 162, 2946-2955.
112. Nibbs, R. J., Graham, G. J. (2013) Immune regulation by atypical chemokine receptors. Nat. Rev. Immunol. 13, 815-829.
113. Bonecchi, R., Locati, M., Galliera, E., Vulcano, M., Sironi, M., Fra, A. M., Gobbi, M., Vecchi, A., Sozzani, S., Haribabu, B., Van Damme, J., Mantovani, A. (2004) Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J. Immunol. 172, 4972-4976.
114. Savino, B., Borroni, E. M., Torres, N. M., Proost, P., Struyf, S., Mortier, A., Mantovani, A., Locati, M., Bonecchi, R. (2009) Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence. J. Biol. Chem. 284, 26207-26215.
115. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., Lusso, P. (1995) Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.
116. Feng, Y., Broder, C. C., Kennedy, P. E., Berger, E. A. (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
117. Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., Landau, N. R. (1996) Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-666.
118. Doranz, B. J., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C., Parmentier, M., Collman, R. G., Doms, R. W. (1996) A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149-1158.
119. Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski, J., Springer, T. A. (1996) The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-833.
120. Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J. L., Arenzana-Seisdedos, F., Schwartz, O., Heard, J. M., Clark-Lewis, I., Legler, D. F., Loetscher, M., Baggiolini, M., Moser, B. (1996) The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833-835.
121. Villalba, S., Salvucci, O., Aoki, Y., DeLa Luz Sierra, M., Gupta, G., Davis, D., Wyvill, K., Little, R., Yarchoan, R., Tosato, G. (2003) Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J. Leukoc. Biol. 74, 880-888.
122. Antonsson, B., De Lys, P., Dechavanne, V., Chevalet, L., Boschert, U. (2010) In vivo processing of CXCL12a/SDF-1a after intravenous and subcutaneous administration to mice. Proteomics 10, 4342-4351.
123. Wang, W., Choi, B. K., Li, W., Lao, Z., Lee, A. Y., Souza, S. C., Yates, N. A., Kowalski, T., Pocai, A., Cohen, L. H. (2014) Quantification of intact and truncated stromal cell-derived factor-1a in circulation by immunoaffinity enrichment and tandem mass spectrometry. J. Am. Soc. Mass Spectrom. 25, 614-625.
124. Richter, R., Jochheim-Richter, A., Ciuculescu, F., Kollar, K., Seifried, E., Forssmann, U., Verzijl, D., Smit, M. J., Blanchet, X., von Hundelshausen, P., Weber, C., Forssmann, W. G., Henschler, R. (2014) Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. Stem Cells Dev. 23, 1959-1974.
125. Menten, P., Struyf, S., Schutyser, E., Wuyts, A., De Clercq, E., Schols, D., Proost, P., Van Damme, J. (1999) The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J. Clin. Invest. 104, R1-R5.
126. Nibbs, R. J., Yang, J., Landau, N. R., Mao, J. H., Graham, G. J. (1999) LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 274, 17478-17483.
127. Gonzalez, E., Kulkarni, H., Bolivar, H., Mangano, A., Sanchez, R., Catano, G., Nibbs, R. J., Freedman, B. I., Quinones, M. P., Bamshad, M. J., Murthy, K. K., Rovin, B. H., Bradley, W., Clark, R. A., Anderson, S. A., O’connell, R. J., Agan, B. K., Ahuja, S. S., Bologna, R., Sen, L., Dolan, M. J., Ahuja, S. K. (2005) The influence of CCL3L1 genecontaining segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434-1440.
128. Shostakovich-Koretskaya, L., Catano, G., Chykarenko, Z. A., He, W., Gornalusse, G., Mummidi, S., Sanchez, R., Dolan, M. J., Ahuja, S. S., Clark, R. A., Kulkarni, H., Ahuja, S. K. (2009) Combinatorial content of CCL3L and CCL4L gene copy numbers influence HIV-AIDS susceptibility in Ukrainian children. AIDS 23, 679-688.
129. Favre-Kontula, L., Johnson, Z., Steinhoff, T., Frauenschuh, A., Vilbois, F., Proudfoot, A. E. (2006) Quantitative detection of therapeutic proteins and their metabolites in serum using antibody-coupled ProteinChip Arrays and SELDI-TOF-MS. J. Immunol. Methods 317, 152-162.
130. Busso, N., Wagtmann, N., Herling, C., Chobaz-Pèclat, V., Bischof-Delaloye, A., So, A., Grouzmann, E. (2005) Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am. J. Pathol. 166, 433-442.
131. Forssmann, U., Stoetzer, C., Stephan, M., Kruschinski, C., Skripuletz, T., Schade, J., Schmiedl, A., Pabst, R., Wagner, L., Hoffmann, T., Kehlen, A., Escher, S. E., Forssmann, W. G., Elsner, J., von Hörsten, S. (2008) Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 181, 1120-1127.
132. Casrouge, A., Decalf, J., Ahloulay, M., Lababidi, C., Mansour, H., Vallet-Pichard, A., Mallet, V., Mottez, E., Mapes, J., Fontanet, A., Pol, S., Albert, M. L. (2011) Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 121, 308-317.
133. Ragab, D., Laird, M., Duffy, D., Casrouge, A., Mamdouh, R., Abass, A., Shenawy, D. E., Shebl, A. M., Elkashef, W. F., Zalata, K. R., Kamal, M., Esmat, G., Bonnard, P., Fontanet, A., Rafik, M., Albert, M. L. (2013) CXCL10 antagonism and plasma sDPPIV correlate with increasing liver disease in chronic HCV genotype 4 infected patients. Cytokine 63, 105-112.
134. Riva, A., Laird, M., Casrouge, A., Ambrozaitis, A., Williams, R., Naoumov, N. V., Albert, M. L., Chokshi, S. (2014) Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology 60, 487-496.
135. Casrouge, A., Bisiaux, A., Stephen, L., Schmolz, M., Mapes, J., Pfister, C., Pol, S., Mallet, V., Albert, M. L. (2012) Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin. Exp. Immunol. 167, 137-148.
136. Narducci, M. G., Scala, E., Bresin, A., Caprini, E., Picchio, M. C., Remotti, D., Ragone, G., Nasorri, F., Frontani, M., Arcelli, D., Volinia, S., Lombardo, G. A., Baliva, G., Napolitano, M., Russo, G. (2006) Skin homing of Sèzary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 107, 1108-1115.
137. Christopherson, K. W., Cooper, S., Hangoc, G., Broxmeyer, H. E. (2003) CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD262/2 mice. Exp. Hematol. 31, 1126-1134.
138. Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., Sandbank, J., Zipori, D., Lapidot, T. (2002) G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol. 3, 687-694.
139. Lèvesque, J. P., Hendy, J., Takamatsu, Y., Simmons, P. J., Bendall, L. J. (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111, 187-196.
140. Cho, S. Y., Xu, M., Roboz, J., Lu, M., Mascarenhas, J., Hoffman, R. (2010) The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 70, 3402-3410.
141. Peled, A., Petit, I., Kollet, O., Magid, M., Ponomaryov, T., Byk, T., Nagler, A., Ben-Hur, H., Many, A., Shultz, L., Lider, O., Alon, R., Zipori, D., Lapidot, T. (1999) Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 283, 845-848.
142. Khurana, S., Margamuljana, L., Joseph, C., Schouteden, S., Buckley, S. M., Verfaillie, C. M. (2013) Glypican-3-mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance. Blood 121, 2587-2595.
143. Davoodi, J., Kelly, J., Gendron, N. H., MacKenzie, A. E. (2007) The Simpson-Golabi-Behmel syndrome causative glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26. Proteomics 7, 2300-2310.
144. Farag, S. S., Srivastava, S., Messina-Graham, S., Schwartz, J., Robertson, M. J., Abonour, R., Cornetta, K., Wood, L., Secrest, A., Strother, R. M., Jones, D. R., Broxmeyer, H. E. (2013) In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 22, 1007-1015.
145. Vèlez de Mendizábal, N., Strother, R. M., Farag, S. S., Broxmeyer, H. E., Messina-Graham, S., Chitnis, S. D., Bies, R. R. (2014) Modelling the sitagliptin effect on dipeptidyl peptidase-4 activity in adults with haematological malignancies after umbilical cord blood haematopoietic cell transplantation. Clin. Pharmacokinet. 53, 247-259.